Clinical data | |
---|---|
Trade names | Detrol, Detrusitol, others |
Other names | PNU-200583E |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699026 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 77% |
Protein binding | Approximately 96.3% |
Elimination half-life | 1.9–3.7 hours |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.232.068 |
Chemical and physical data | |
Formula | C22H31NO |
Molar mass | 325.496 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Tolterodine, sold under the brand name Detrol among others, is a medication used to treat frequent urination, urinary incontinence, or urinary urgency.[5] Effects are seen within an hour.[6] It is taken by mouth.[6][7]
Common side effects include headache, dry mouth, constipation, and dizziness.[6] Serious side effects may include angioedema, urinary retention, and QT prolongation.[6] Use in pregnancy and breastfeeding are of unclear safety.[5][8] It works by blocking muscarinic receptors in the bladder thus decreasing bladder contractions.[6]
Tolterodine was approved for medical use in 1998.[6] It is available as a generic medication.[5] In 2020, it was the 271st most commonly prescribed medication in the United States, with more than 1 million prescriptions.[9][10]